1Point Pharma ApS: Financial statements 2025
CVR: 44804425
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
1Point Pharma ApS (CVR 44804425) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -1,313,951 and a net result of DKK -1,484,861. Equity in the 2025 report amounted to DKK 932,458. The solvency ratio was 27%. The company had 4 employees in the financial year.
- Gross Profit
- DKK -1,313,951
- Profit/Loss
- DKK -1,484,861
- Equity
- DKK 932,458
- Total Assets
- DKK 3,450,752
- Employees
- 4
Official annual report
How creditworthy is 1Point Pharma ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
1Point Pharma ApS has published its interim report for the period April 29, 2024 – December 31, 2024.
About 1Point Pharma ApS
1Point Pharma ApS is a Danish company of the type Anpartsselskab based in København V, founded in 2024. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Morten Carl Madsen. The board consists of Morten Carl Madsen (chair), Flemming Sylvang Videriksen, Michael Lundorff-Hansen and Pernille Hasfeldt Lund. The company's owners include Holdingselskabet House of Lundorff APS, Lease-A-Brain ApS and GJ Invest ApS. According to the 2025 annual report, the company had an average of 4 employees. In 2025, the company reported a gross profit of DKK -1,313,951 and a net result of DKK -1,484,861. Equity in the 2025 report amounted to DKK 932,458.